CORRECTION



Correction to: Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis

Tomoko Fujii^{1,2}, Riki Ganeko³, Yuki Kataoka⁴, Toshi A. Furukawa⁵, Robin Featherstone⁶, Kent Doi⁷, Jean-Louis Vincent⁸, Daniela Pasero⁹, René Robert¹⁰, Claudio Ronco¹¹ and Sean M. Bagshaw^{12*}

© 2018 Springer-Verlag GmbH Germany, part of Springer Nature and ESICM

Correction to: Intensive Care Med

https://doi.org/10.1007/s00134-017-5004-9 Owing to an oversight by the authors, Fig. 2 in this article was not the version intended for publication. The correct Fig. 2, reproduced here, features footnote symbols and Fig. 2b includes three studies as described in the main text.

*Correspondence: bagshaw@ualberta.ca ¹² Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440-112 ST NW, Edmonton, Canada T6G 2B7 Full author information is available at the end of the article

The original article can be found online at https://doi.org/10.1007/s00134-017-5004-9.



Study or Subgroup L.1.1 Abdominal seps	PMX-H	HP S	Standard th	nerapy		Risk Ratio		Risk Ratio
1.1 Abdominal seps	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
and the additional seps	is							
incent 2005	5	17	5	18	6.6%	1.06 [0.37, 3.02]	2005	
Cruz 2009	11	34	16	30	17.5%	0.61 [0.34, 1.09]	2009	
Payen 2015	33	119	22	113	24.1%	1.42 [0.89, 2.29]	2015	
Subtotal (95% CI)		170		161	48.3%	0.98 [0.54, 1.78]		
Total events	49	-	43					
Heterogeneity: Tau² = ! Test for overall effect: 2				P = 0.08);	l ² = 60%			
1.1.2 Sepsis with vario	ous etiol	ogies in	ncluding al	bdomina	I			
Cantaluppi 2008	2	8	3	8	3.4%	0.67 [0.15, 2.98]	2008	
EUPHRATES 2017 *	84	224	78	226	48.4%	1.09 [0.85, 1.39]		_ _
Subtotal (95% CI)		232		234	51.7%	1.07 [0.84, 1.37]		
Total events	86		81					
Heterogeneity: Tau ² = 0 Test for overall effect: 2				9 = 0.53);	$ ^2 = 0\%$			
Total (95% CI)		402		395	100.0%	1.03 [0.78, 1.36]		+
Total events	135		124					
Heterogeneity: Tau ² = (P = 0.25)	$l^2 = 25\%$			0.1 0.2 0.5 1 2 5
Test for overall effect: 2								Favours PMX-HP Favours Standard therapy
Test for subgroup diffe	rences: C	$hi^2 = 0.$	08, df = 1	(P = 0.78)	3), 1 ² = 0%	6		······
	PMX-H		Standard th			Risk Ratio		Risk Ratio
Study or Subgroup Vincent 2005	Events 1	Total 17	Events 0	Total 18	13.8%	M-H, Random, 95% Cl 3.17 [0.14, 72.80]	2005	Risk Ratio M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015	Events 1 6	Total 17 119	Events 0 3	Total 18 113	13.8% 73.0%	M-H, Random, 95% Cl 3.17 [0.14, 72.80] 1.90 [0.49, 7.41]	2005 2015	
Study or Subgroup Vincent 2005 Payen 2015	Events 1	Total 17	Events 0	Total 18	13.8%	M-H, Random, 95% Cl 3.17 [0.14, 72.80]	2005 2015	
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 *	Events 1 6	Total 17 119	Events 0 3	Total 18 113 226	13.8% 73.0%	M-H, Random, 95% Cl 3.17 [0.14, 72.80] 1.90 [0.49, 7.41]	2005 2015	
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events	Events 1 6	Total 17 119 224	Events 0 3	Total 18 113 226	13.8% 73.0% 13.3%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90]	2005 2015	
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events	Events 1 6 1 8	Total 17 119 224 360	Events 0 3 0 3	Total 18 113 226 357	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90]	2005 2015 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0	Events	Total 17 119 224 360 $2^{2} = 0.13$	Events 0 3 0 3, df = 2 (F	Total 18 113 226 357	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90]	2005 2015 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0	Events	Total 17 119 224 360 $2^{2} = 0.13$	Events 0 3 0 3, df = 2 (F	Total 18 113 226 357	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90]	2005 2015 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0	Events	Total 17 119 224 360 $2^{2} = 0.13$	Events 0 3 0 3, df = 2 (F	Total 18 113 226 357	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90]	2005 2015 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2	Events 1 6 1 0.00; Chi 2 = 1.30	Total 17 119 224 360 $^2 = 0.12$ (P = 0.12)	Events 0 3 0 3, df = 2 (P	Total 18 113 226 357 2 = 0.93);	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94]	2005 2015 2017	M-H, Random, 95% CI
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX-	Total 17 119 224 360 ² = 0.1: (P = 0.1) HP	Events 0 3 0 3 3 4 10 3 3 3 4 3 3 4 4 5 4 5 4 5 4 4 5 5 5 5 6 6 6 6 7 6 7 6 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 </td <td>Total 18 113 226 357 ¹ = 0.93); d therapy</td> <td>13.8% 73.0% 13.3% 100.0%</td> <td>M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference</td> <td>2005 2015 2017</td> <td>M-H, Random, 95% CI</td>	Total 18 113 226 357 ¹ = 0.93); d therapy	13.8% 73.0% 13.3% 100.0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference	2005 2015 2017	M-H, Random, 95% CI
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S	Total 17 119 224 360 ² = 0.1: (P = 0.1) (P = 0.1) HP D Tota	Events 0 3 0 3, df = 2 (F 19) Standar I Mean	Total 18 113 226 357 ² = 0.93); ⁴ = 0.93); ⁵ = 0.93); ⁵ = 0.93); ⁶ = 0.93);	13.8% 73.0% 13.3% 100.0% ² = 0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference ht IV, Random, 95% C	2005 2015 2017 2017	M-H, Random, 95% CI
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = (Test for overall effect: 2 Study or Subgroup	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4.	Total 17 119 224 360 ² = 0.13 (P = 0.13) (P = 0.13) HP D Tota 4	Events 0 3 0 3, df = 2 (F) Standar 1 Mean 7	Total 18 113 226 357 2 = 0.93); d therapy <u>SD</u> To 4.4	13.8% 73.0% 13.3% 100.0% ² = 0% tal Weig 18 15.8	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference ht V, Random, 95% C 5% -0.11 [-0.77, 0.55	2005 2015 2017 2017 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity. Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 *	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3.	Total 17 119 224 360 $^2 = 0.13$ (P = 0.1) HP D Total 4 17	Events 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 0 3 10 4 3 10 4 3 10 4 3 10 4 3 10 4 3 10 4 3 10 4 3 10 4 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 <th10< th=""> 10 <th10< th=""> 10 <th10< th=""></th10<></th10<></th10<>	Total 18 113 226 357 ² = 0.93); ⁴ = 0.93); ⁵ = 0.93); ⁵ = 0.93);	13.8% 73.0% 13.3% 100.0% ² = 0% (tal Weig 18 15.8 8 9.3	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference ht IV, Random, 95% CI 3% -0.11 [-0.77, 0.55 1% -0.98 [-2.04, 0.07	2005 2015 2017 1 Year 2017 2017 2017 2017 2017 2005 2005 2005	M-H, Random, 95% CI
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 * Cruz 2009 †	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3. -3.4 2.	Total 17 119 224 360 $^2 = 0.13$ (P = 0.3) HP D Tota 4 9	Events 0 0 3 0 3 0 3 3 df = 2 (F 9 Standar 9 1 10.4 -0.1	Total 18 113 226 357 ² = 0.93); ² = 0.93); ⁴ = 0.93); 5D To 4.4 5.9 4.3	13.8% 73.0% 13.3% 100.0% ² = 0% (tal Weig 18 15.1 8 9.1 30 19.6	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Std. Mean Difference IV, Random, 95% C 8% -0.11 [-0.77, 0.55 × -0.98 [-2.04, 0.07 5% -0.90 [-1.42, -0.38	2005 2015 2017 2017 2017 2017 2017 2017 2008 2009 2008	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 * Cruz 2009 † Payen 2015	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3. -3.4 3. -3.4 3. 8.3 3.	Total 17 119 224 360 $^2 = 0.13$ (P = 0.12) HP D 4 4 9 6	Events 0 3 0 3, df = 2 (F) Standar 1 Mean 7 9 10.4 -0.1 -7.5	Total 18 113 226 357 9 = 0.93); 9 = 0.93); 9 = 0.93); 9 = 0.93); 10 = 0.93); 11 = 0.93); 12 = 0.93); 13 = 0.93); 14 = 0.93); 15 = 0.93); 15 = 0.93); 15 = 0.93); 16 = 0.93); 17 = 0.93); 17 = 0.93); 17 = 0.93); 18 = 0.93); 19 = 0.93); 19 = 0.93); 19 = 0.93); 10 = 0.93); 10 = 0.93); 10 = 0.93); 10 = 0.93); 11 = 0.93); 11 = 0.93); 11 = 0.93); 12 = 0.93); 12 = 0.93); 12 = 0.93); 13 = 0.93); 13 = 0.93); 13 = 0.93); 14 = 0.93); 15 = 0.93); 15 = 0.93); 15 = 0.93); 16 = 0.93); 17 = 0.93); 17 = 0.93); 17 = 0.93); 18 = 0.93); 19 = 0.93); 19 = 0.93); 19 = 0.93); 19 = 0.93); 19 = 0.93); 19 = 0.93); 10 = 0.	13.8% 73.0% 13.3% 100.0% ² = 0% (tal Weig 18 15.8 8 9.3 30 19.6 30 19.6	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Value Value Value Value 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Value Va	2005 2015 2017 2017 2017 2017 2017 2017 2008 2009 2008 2009 2009 2009 2009	M-H, Random, 95% CI
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity. Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 * Cruz 2009 † Payen 2015 EUPHRATES 2017 *†	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3. -3.4 2.	Total 17 119 224 360 $^2 = 0.13$ (P = 0.13) (P = 0.13) D Total 4 9 34 6 119 7 224	Standari 1 Mean 7 9 3 10.4 -0.1 7.5 -1.6 -1.6	Total 18 113 226 357 2 = 0.93); 4 therapy 5D To 4.4 5.9 4.3 3.5 1 3.3 2	13.8% 73.0% 13.3% 100.0% ² = 0% ² = 0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Variation Variation Variation Variation 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Variation Variation <	2005 2015 2017 2017 2017 2017 2005 2005 2008 3] 2009 3] 2009 3] 2015 7] 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 * Cruz 2009 † Payen 2015 EUPHRATES 2017 *† Total (95% CI)	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3. -3.4 2. 8.3 3. -2 3.	Total 17 119 224 360 $^2 = 0.1$ (P = 0.1) (P = 0.1) D Tota 4 9 6 7 224	Events 0 3 0 3, df = 2 (F 9 10.4 9 10.4 -0.1 7.5 -1.6	Total 18 113 226 357 2 = 0.93); 4 therapy <u>5D</u> To 4.4 5.9 4.3 3.5 1 3.3 2 3	13.8% 73.0% 13.3% 100.0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Contemporal Statement of the statement of t	2005 2015 2017 2017 2017 2017 2005 2005 2008 3] 2009 3] 2009 3] 2015 7] 2017	M-H, Random, 95% Cl
Study or Subgroup Vincent 2005 Payen 2015 EUPHRATES 2017 * Total (95% CI) Total events Heterogeneity: Tau ² = 0 Test for overall effect: 2 Study or Subgroup Vincent 2005 * Cantaluppi 2008 * Cruz 2009 † Payen 2015 EUPHRATES 2017 *†	Events 1 6 1 8 0.00; Chi 2 = 1.30 PMX- Mean S 8.5 4. 5.4 3. -3.4 2. 8.3 3. -2 3. 0.12; Chi ³	Total 17 119 224 360 $2^2 = 0.12$ (P = 0.12) (P = 0.12) HP D Tota 4 7 224 402 2 2	Standard 0 3 0 3 3, df = 2 (F 9 10.4 9.3 10.4 9.7.5 -1.6 2 4, df = 4 (f	Total 18 113 226 357 2 = 0.93); 4 therapy <u>5D</u> To 4.4 5.9 4.3 3.5 1 3.3 2 3	13.8% 73.0% 13.3% 100.0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0% ² = 0%	M-H, Random, 95% CI 3.17 [0.14, 72.80] 1.90 [0.49, 7.41] 3.03 [0.12, 73.90] 2.17 [0.68, 6.94] Contemporal Statement of the statement of t	2005 2015 2017 2017 2017 2017 2005 2005 2008 3] 2009 3] 2009 3] 2015 7] 2017	M-H, Random, 95% CI

Author details

¹ Department of Epidemiology and Preventive Medicine, Kyoto University Graduate School of Medicine, Yoshida Hon-machi, Sakyo-ku, Kyoto, Japan.
² Japan Society for the Promotion of Science, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo, Japan. ³ Department of Surgery, Kyoto University Hospital, 54 Kawaharacho, Syogoin, Sakyo-ku, Kyoto, Japan. ⁴ Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Higashi-Naniwa-Cho 2-17-77, Amagasaki, Hyogo, Japan. ⁵ Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine, Yoshida Konoe-cho, Sakyo-Ku, Kyoto, Japan. ⁶ Department of Pediatrics, Alberta Research Center for Health Evidence (ARCHE), University of Alberta, 11405-87 Avenue Edmonton, Alberta, Canada. ⁷ Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. ⁸ Department of Intensive Care, Erasme University Hospital, Unversité Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium. ⁹ Department of Anesthesia and Intensive Care Medicine, San Giovanni Battista Hospital, University of Turin, Via Giuseppe Verdi, 8, 10124 Turin, Italy. ¹⁰ Service de Réanimation Médicale, CHU-Poitiers, University of Poitiers, 86000 Poitiers, France. ¹¹ Department of Nephrology Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy. ¹² Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440-112 ST NW, Edmonton, Canada T6G 2B7.

Published online: 16 January 2018